Ascentage Pharma (AAPG) 6-K furnishes HKEX board meeting notice

Rhea-AI Filing Summary

Ascentage Pharma Group International submitted a Form 6-K noting that it has furnished a Hong Kong Stock Exchange announcement titled “Notice of Board Meeting.” The announcement, dated August 8, 2025, is attached as Exhibit 99.1. The report is signed by Chief Executive Officer Dajun Yang.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

On August 8, 2025, Ascentage Pharma Group International posted an announcement on the Hong Kong Stock Exchange entitled, “Notice of Board Meeting”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.

1

INDEX TO EXHIBITS

Exhibit Number		Exhibit Title
99.1		Announcement dated August 8, 2025

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: August 8, 2025	/s/ Dajun Yang
	Name: Dajun Yang
	Title:   Chief Executive Officer

3

FAQ

What did Ascentage Pharma Group International (AAPG) report on its August 2025 Form 6-K?

Ascentage Pharma Group International reported the furnishing of a Hong Kong Stock Exchange announcement titled “Notice of Board Meeting.” The announcement, dated August 8, 2025, is attached as Exhibit 99.1 and is the primary subject of this Form 6-K.

What is Exhibit 99.1 in Ascentage Pharma Group International (AAPG)'s August 2025 Form 6-K?

Exhibit 99.1 is an announcement dated August 8, 2025 titled “Notice of Board Meeting.” Ascentage Pharma Group International posted this announcement on the Hong Kong Stock Exchange and then furnished it as an exhibit to its Form 6-K report.

Which annual report form does Ascentage Pharma Group International (AAPG) use with the SEC?

Ascentage Pharma Group International files its annual reports under cover of Form 20-F. This classification reflects its status as a foreign private issuer reporting under U.S. securities laws while being primarily listed and operating outside the United States.

Who signed Ascentage Pharma Group International (AAPG)'s August 2025 Form 6-K and in what capacity?

The Form 6-K was signed by Dajun Yang as Chief Executive Officer of Ascentage Pharma Group International. His signature confirms that he is duly authorized to sign on behalf of the registrant under the Securities Exchange Act of 1934.

Where are Ascentage Pharma Group International (AAPG)'s principal executive offices located?

Ascentage Pharma Group International’s principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China. This address is listed as the company’s main executive location in the Form 6-K filed as a foreign private issuer.